ADAP Logo

Adaptimmune Therapeutics plc (ADAP) 

NASDAQ
Market Cap
$209.75M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
414 of 776
Rank in Industry
217 of 433

Largest Insider Buys in Sector

ADAP Stock Price History Chart

ADAP Stock Performance

About Adaptimmune Therapeutics plc

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States and the United Kingdom. The company's specific peptide enhanced affinity receptor (SPEAR) T-cell platform enables it to identify cancer targets. It is developing ADP-A2M4 that is in phase II clinical trials with SPEARHEAD-1 for synovial sarcoma and myxoid round cell liposarcoma indications (MRCLS); in phase II clinical trials with SPEARHEAD-2 for patients with head and …

Insider Activity of Adaptimmune Therapeutics plc

Over the last 12 months, insiders at Adaptimmune Therapeutics plc have bought $0 and sold $147,201 worth of Adaptimmune Therapeutics plc stock.

On average, over the past 5 years, insiders at Adaptimmune Therapeutics plc have bought $10.09M and sold $1.87M worth of stock each year.

There was no buying activity among insiders over the last 12 months.

The last purchase of 39,000 shares for transaction amount of $11,326 was made by Wood Gavin (Chief Financial Officer) on 2022‑05‑20.

List of Insider Buy and Sell Transactions, Adaptimmune Therapeutics plc

2024-06-18SaleChief Commercial Officer
24,531
0.0086%
$0.93$22,814+14.77%
2024-01-17SaleChief Executive Officer
30,080
0.0124%
$0.67$20,244+55.24%
2024-01-17SaleChief Medical Officer
18,276
0.0075%
$0.67$12,300+55.24%
2024-01-17SaleChief Patient Supply Officer
18,114
0.0075%
$0.67$12,191+55.24%
2024-01-17SaleChief Operating Officer
18,908
0.0078%
$0.67$12,725+55.24%
2024-01-16SaleChief Executive Officer
9,304
0.0046%
$0.79$7,350+56.32%
2024-01-16SaleChief Patient Supply Officer
4,681
0.0023%
$0.79$3,698+56.32%
2024-01-16SaleChief Operating Officer
4,681
0.0023%
$0.79$3,698+56.32%
2024-01-16SaleChief Medical Officer
2,287
0.0011%
$0.79$1,807+56.32%
2024-01-12SaleChief Executive Officer
17,257
0.0078%
$0.85$14,739+34.61%
2024-01-12SaleChief Medical Officer
7,799
0.0035%
$0.85$6,661+34.61%
2024-01-12SaleChief Patient Supply Officer
5,220
0.0024%
$0.85$4,458+34.61%
2024-01-12SaleChief Operating Officer
5,220
0.0024%
$0.85$4,458+34.61%
2024-01-11SaleChief Executive Officer
11,945
0.005%
$0.84$9,994+28.71%
2024-01-11SaleChief Medical Officer
4,009
0.0017%
$0.84$3,354+28.71%
2024-01-11SaleChief Patient Supply Officer
4,009
0.0017%
$0.84$3,354+28.71%
2024-01-11SaleChief Operating Officer
4,009
0.0017%
$0.84$3,354+28.71%
2023-09-01SaleChief Executive Officer
2,403
0.001%
$0.78$1,874+25.28%
2023-08-01SaleChief Patient Supply Officer
3,096
0.0013%
$0.91$2,804-5.26%
2023-07-10Saledirector
47,702
0.0283%
$0.91$43,447-5.56%

Insider Historical Profitability

<0.0001%
Bertrand William C JRChief Operating Officer
7785
0.003%
$0.82118+23.78%
BARRIS PETER J10 percent owner
82978668
32.4511%
$0.8270<0.0001%
BARRETT M JAMES10 percent owner
82978668
32.4511%
$0.8270<0.0001%
KERINS PATRICK J10 percent owner
82978668
32.4511%
$0.8270<0.0001%
Viswanathan Ravi10 percent owner
82978668
32.4511%
$0.8270<0.0001%

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
Matrix Capital Management Company, L.P.$61.58M15.2538.97M0%+$00.57
Ecor1 Capital Llc$43.3M10.7227.4MNew+$43.3M0.3
Nea Management Company Llc$26.99M6.6817.08M0%+$00.13
Baillie Gifford Co$25.08M6.2115.87M-0.25%-$63,618.700.02
Baker Bros Advisors LP$17.04M4.2210.79M-1.66%-$287,970.800.12
Prismo does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. Prismo does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.